Market Place
Sourcing Support
RGNX Stockholders: Contact Robbins LLP for Class Action
19 Mar 2026 //
PHARMIWEB
RGNX`s Inadequate Risk Disclosures Allegedly Cost $2.40/Share
10 Mar 2026 //
PHARMIWEB
REGENXBIO Presents At 2026 (MDA) Clinical & Scientific Conference
04 Mar 2026 //
PR NEWSWIRE
US court revives Regenxbio Patent Lawsuit over DMD
21 Feb 2026 //
REUTERS
Robbins LLP Alerts Regenxbio Investors On Lawsuit
16 Feb 2026 //
PHARMIWEB
REGENXBIO To Present At J.P. Morgan Healthcare Conference
18 Dec 2025 //
PR NEWSWIRE
REGENXBIO To Participate In Upcoming Investor Conference
25 Nov 2025 //
PR NEWSWIRE
Regenxbio Reports Strong Q2 2025 Financials and Operational
08 Aug 2025 //
PR NEWSWIRE
REGENXBIO`s Q2 2025 Financial Results Discussion on August 7
31 Jul 2025 //
PR NEWSWIRE
Regenxbio Reports Q1 2025 Financial Results and Highlights
12 May 2025 //
PR NEWSWIRE
Regenxbio Appoints Chief Financial Officer
17 Sep 2024 //
CONTRACT PHARMA
REGENXBIO Announces Positive Long-Term Data for RGX-121 Pivotal Dose
03 Sep 2024 //
PR NEWSWIRE
REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202
01 Aug 2024 //
PR NEWSWIRE
REGENXBIO Expands AFFINITY DUCHENNE® Trial To Include Younger Patients
24 Jun 2024 //
PR NEWSWIRE
Regenxbio Updates Leadership, Names New CEO
12 Jun 2024 //
CONTRACT PHARMA
REGENXBIO to Participate in Cantor Fitzgerald`s Virtual DMD and Other Dystrophy Days
27 Mar 2024 //
PRESS RELEASE
REGENXBIO to Participate in Upcoming Investor Conferences
11 Mar 2024 //
PRESS RELEASE
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock
06 Mar 2024 //
PRESS RELEASE
REGENXBIO Announces Proposed Public Offering of Common Stock
06 Mar 2024 //
PR NEWSWIRE
Regenxbio Announces New Initial Efficacy Data From Affinity Duchenne® Trial
05 Mar 2024 //
PR NEWSWIRE
REGENXBIO’s Research and Development Facility, Maryland, US
01 Mar 2024 //
PHARMACEUTICAL TECHNOLOGY
REGENXBIO to Host Webcast to Discuss Data from Ph I/II AFFINITY DUCHENNE® Trial
29 Feb 2024 //
PR NEWSWIRE
REGENXBIO to Host Event to Discuss Data from Phase I/II AFFINITY DUCHENNE Trial
29 Feb 2024 //
PRESS RELEASE
REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
PR NEWSWIRE
REGENXBIO to Host Conference to Discuss Q4 and Full Year 2023 Financial Results
21 Feb 2024 //
PRESS RELEASE
REGENXBIO Announces Completion of Enrollment in AFFINITY DUCHENNE® Trial
07 Feb 2024 //
PRESS RELEASE
REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024
31 Jan 2024 //
PRESS RELEASE
REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting
10 Jan 2024 //
PRESS RELEASE
REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial
29 Nov 2023 //
PRESS RELEASE
SQZ lays off 80% of staff, Regenxbio cuts 15%
09 Nov 2023 //
FIERCE BIOTECH
REGENXBIO Announces Updated Third Quarter 2023 Financial Results
08 Nov 2023 //
PR NEWSWIRE
REGENXBIO to Participate in Upcoming Investor Conferences
07 Nov 2023 //
PRESS RELEASE
REGENXBIO to Host Conference to Discuss Third Quarter 2023 Financial Results
01 Nov 2023 //
PRESS RELEASE
REGENXBIO Announces Presentations at 2023 Annual Meeting
30 Oct 2023 //
PRESS RELEASE
REGENXBIO to Participate in the Jefferies CNS/Neuro Summit
05 Oct 2023 //
PRESS RELEASE
Regenxbio up after hours on early-stage Duchenne candidate
03 Oct 2023 //
SEEKING ALPHA
BioLineRx Reports 2Q 2023 FYR and Recent Corporate and Portfolio Updates
30 Aug 2023 //
PR NEWSWIRE
REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors
23 Aug 2023 //
PR NEWSWIRE
REGENXBIO Reports Second Quarter 2023 Financial Results
02 Aug 2023 //
PR NEWSWIRE
REGENXBIO Announces Participation at 2023 Wedbush PacGrow Healthcare Conference
01 Aug 2023 //
PRESS RELEASE
REGENXBIO Reports 1Q 2023 Financial Results and Recent Operational Highlights
03 May 2023 //
BUSINESSWIRE
REGENXBIO Announces Presentations at the 26th Annual Meeting
02 May 2023 //
PRESS RELEASE
Chasing Pfizer, Regenxbio benefits from FDA boost in DMD
11 Apr 2023 //
FIERCE BIOTECH
REGENXBIO to Participate in Upcoming Investor Conferences
08 Mar 2023 //
PR NEWSWIRE
Regenxbio Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results
28 Feb 2023 //
PR NEWSWIRE
REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease
21 Dec 2022 //
PRNEWSWIRE
Regenxbio concludes subject dosing in Phase I/II severe MPS I trial
09 Dec 2022 //
CLINICALTRIALSARENA
REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111
08 Dec 2022 //
PRNEWSWIRE
REGENXBIO Presents Data from and the Expansion of PII ALTITUDE Trial of RGX-314
03 Nov 2022 //
PRNEWSWIRE
REGENXBIO Announces Presentation at Chardan`s Genetic Medicines Conference
27 Sep 2022 //
PRNEWSWIRE
REGENXBIO Presents Interim Data from the PI/II/III CAMPSIITE Trial of RGX-121
31 Aug 2022 //
PRNEWSWIRE
RegenXBio gets FDA support for accelerated gene therapy filing
04 Aug 2022 //
FIERCEBIOTECH
REGENXBIO Reports Second Quarter 2022 Financial Results
03 Aug 2022 //
PRNEWSWIRE
Amgen, GSK, Regenxbio and others urge SCOTUS to review `damaging` decision
19 Jul 2022 //
ENDPTS
Regenxbio set for commercial era with new plant, AbbVie deal
13 Jul 2022 //
FIERCEPHARMA
REGENXBIO Announces Enrollment Complete in Cohort 5 of Phase II AAVIATE® Trial
08 Jul 2022 //
PRNEWSWIRE
Regenxbio opens gene therapy manufacturing facility at its Maryland HQ
11 Jun 2022 //
ENDPTS
Novartis Loses Bid To Make FDA Block Patent Term Extension
19 Mar 2022 //
LAW360
REGENXBIO Announces Presentations at 11th Annual SVB Leerink Conference
08 Feb 2022 //
PRNEWSWIRE
